. Author manuscript; available in PMC: 2012 May 1.

Published in final edited form as: Trends Mol Med. 2011 Mar 8;17(5):244–251. doi: 10.1016/j.molmed.2011.01.007

Table 2.

Major clinical information for CNVs in pharmacogenetic genes.

	CNV type	Drug affected	Phenotype	Clinical indication	PharmGKB gene category	Reference
**CYP2A64***	Deletion	Nicotine Coumarin Tegafur	No enzyme activity	Unknown	VIP	[90–92]
**CYP2A61x2***	Duplication	Nicotine Coumarin Tegafur	Increased enzyme activity	Unknown	VIP	[90–92]
**CYP2D61×N***	Multiplication	Anticholinesterases Antidepressants Antipsychotics Beta Blocking Agents Opioids	Increased enzyme activity	Alzheimer Disease Depression Hypertension Breat cancer Codeine dependence	VIP	[19]
**CYP2D62×N***	Multiplication		Increased enzyme activity		VIP
**CYP2D65***	Deletion		No enzyme activity		VIP
**GSTM10***	Deletion	Antineoplastic agent Xenobiotics	No enzyme activity	Breast cancer Non-small cell lung cancer Leukemia Drug toxicity		[93, 94]
**GSTT10***	Deletion	Antineoplastic agent Xenobiotics	No enzyme activity			[93, 94]
*SULT1A1*	Multiplication	Unclear clinic impact on drugs	Increased enzyme activity	Unknown	VIP
*SULT1A3*	Duplication	Unclear clinic impact on drugs	Unknown	Unknown
*UGT2B17*	Deletion	Estradiol Testosterone	Dcreased enzyme activity	Androgen Excretion		[95]

VIP = very important pharmacogene.